Physician profile
Nathan A King
NPI 1366710865
$7,260.66
in general payments reported to CMS, 2019-2025
46 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $910 · 2020: $1,584 · 2021: $1,026 · 2022: $1,059 · 2023: $424 · 2024: $1,036 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,681.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,435.76 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $801.38 | 2020-2025 | |
| Pfizer INC. | $680.45 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $659.41 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $468.91 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $444.79 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $261.38 | 2019-2025 | Trintellix |
| Corcept Therapeutics | $238.95 | 2024-2025 | Korlym |
| Mannkind Corporation | $199.10 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $151.15 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $150.45 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $144.58 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Amarin Pharma, INC. | $133.74 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.81 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $117.51 | 2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.